Avtozma (tocilizumab-anoh)
Biosimilar
- Region
- 🇺🇸 US
- Active substance
- tocilizumab-anoh
- Company
- Celltrion Inc
- Status
- Approved
- FDA approval
- Wed 21 Jan 2026
- Designations
- Biosimilar
- Application
- BLA761498
- Official record
- www.accessdata.fda.gov
Regulatory milestones
Fri 03 Apr 2026🇪🇺 DHPC safety letter
Avtozma (tocilizumab): DHPC sent to healthcare professionals
Medication error, Quality defect; Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Cytokine Release Syndrome, COVID-19 virus infection · source
Wed 21 Jan 2026🇺🇸 FDA approval
FDA approves biosimilar Avtozma (tocilizumab-anoh)
Celltrion Inc; BLA761498; Biosimilar; injectable · source
Follow Avtozma
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.